Annals of Surgical Oncology

, Volume 15, Issue 10, pp 2978–2979 | Cite as

Benefits and Harms in Avoiding Axilla Lymphadenectomy in Breast Cancer

Breast Oncology


  1. 1.
    Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133–44PubMedCrossRefGoogle Scholar
  2. 2.
    Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 2003 Aug;10:718–21CrossRefGoogle Scholar
  3. 3.
    Fatouros M, Roukos DH, Arampatzis I, et al. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 2005; 5:737–45PubMedCrossRefGoogle Scholar
  4. 4.
    Clarke M, Collins R, Darby S, et al. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366:2087–106PubMedGoogle Scholar
  5. 5.
    Reimer T, Fietkau R, Markmann S, et al. How important is the axillary nodal status for adjuvant treatment decisions at a breast cancer multidisciplinary tumor board? A survival analysis. Ann Surg Oncol. 2007 Nov 7 [Epub ahead of print]Google Scholar
  6. 6.
    Chen SL, Hoehne FM, Giuliano AE. The prognostic significance of micrometastases in breast cancer: A SEER population-based analysis. Ann Surg Oncol 2007 Sep 26 [Epub ahead of print]Google Scholar
  7. 7.
    Roukos DH. Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 1998; 80:16–24PubMedGoogle Scholar
  8. 8.
    Roukos DH, Lorenz M, Karakostas K, et al. Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 2001; 84:1602–9PubMedCrossRefGoogle Scholar
  9. 9.
    Siewert JR, Kestlmeier R, Busch R, et al. Benefits of D2 lymph node dissection for patients with gastric cancer and pN0 and pN1 lymph node metastases. Br J Surg 1996; 83:1144–7PubMedCrossRefGoogle Scholar
  10. 10.
    Roukos DH. Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 2000; 7:253–5PubMedCrossRefGoogle Scholar
  11. 11.
    Kappas AM, Fatouros M, Roukos DH. Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 2004; 11:727–30PubMedCrossRefGoogle Scholar
  12. 12.
    Roukos DH. Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 1999; 6:46–56PubMedCrossRefGoogle Scholar
  13. 13.
    Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005; 2:98–107. PubMedCrossRefGoogle Scholar
  14. 14.
    Roukos DH, Hottenrott C, Lorenz M, Koutsogiorgas-Couchell S. A critical evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach. An analysis of early results and long-term survival. J Cancer Res Clin Oncol 1990; 116:307–1PubMedCrossRefGoogle Scholar
  15. 15.
    Roukos DH, Kappas AM. Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 2002; 81:59–62PubMedCrossRefGoogle Scholar
  16. 16.
    Briasoulis E, Liakakos T, Dova L, et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 2006; 6:931–9PubMedCrossRefGoogle Scholar
  17. 17.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11–20PubMedCrossRefGoogle Scholar
  18. 18.
    Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 2007; 14:2691–5PubMedCrossRefGoogle Scholar
  19. 19.
    Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 2002; 9:220–1PubMedGoogle Scholar
  20. 20.
    Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 2004; 11:127–9PubMedCrossRefGoogle Scholar
  21. 21.
    Roukos DH, Hottenrott C, Encke A, et al. Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 1994; 3:115–25PubMedCrossRefGoogle Scholar
  22. 22.
    Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention, new trends in the surgical treatment of hereditary breast ovarian cancer. Ann Surg Oncol 2008; 15:21–33 DOI: 10.1245/s10434-007-9612-4 PubMedCrossRefGoogle Scholar
  23. 23.
    Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007; 357:1555–6; author reply 1556PubMedCrossRefGoogle Scholar
  24. 24.
    Pierce LJ, Levin AM, Rebbeck TR. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006; 24:2437–43PubMedCrossRefGoogle Scholar
  25. 25.
    Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 2002; 9:607–9PubMedCrossRefGoogle Scholar
  26. 26.
    Roukos DH, Agnanti NJ, Paraskevaidis E, et al. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 2002; 9:941–3PubMedGoogle Scholar
  27. 27.
    Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 2004; 11:1030–4PubMedCrossRefGoogle Scholar
  28. 28.
    Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2008; 358:197; author reply 198PubMedCrossRefGoogle Scholar
  29. 29.
    Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007; 6:308–12PubMedGoogle Scholar
  30. 30.
    Gewin V. Missing the mark. Nature 2007; 449:770–1PubMedCrossRefGoogle Scholar
  31. 31.
    Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 2007; 4:578–90PubMedCrossRefGoogle Scholar
  32. 32.
    Liakakos T, Roukos DH. More controversy than ever—challenges, promises towards personalized treatment of gastric cancer. Ann Surg Oncol 2008 Jan 23; [Epub ahead of print] (DOI: 10.1245/s10434-007-9798-5)
  33. 33.
    Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer - integrating current standards and new technologies. Expert Rev Mol Diagn 2008; 8:29–39PubMedCrossRefGoogle Scholar
  34. 34.
    Roukos DH. Linking contralateral breast cancer with genetics. Radiother Oncol 2008 Jan 29; [Epub ahead of print] (DOI: 10.1016/j.radonc.2008.01.013

Copyright information

© Society of Surgical Oncology 2008

Authors and Affiliations

  1. 1.3rd Department of SurgeryAthens UniversityAthensGreece

Personalised recommendations